National Cancer Center Hospital
Tokyo, Japan
Location status: Recruiting
Location contact
Ken Kato, M.D./Ph.D
CONTACT
NCT Number: NCT04328948
This study is conducted to investigate whether modified chemoradiotherapy with elective nodal irradiation reduces the locoregional recurrence that cannot be completely resected by salvage endoscopic resection and preserve esophagus without compromising overall survival.
Interested in participating?
Request Info20 year and older
All sexes
Interventional
Phase 3
Tokyo, Japan
Location status: Recruiting
Ken Kato, M.D./Ph.D
CONTACT
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Chemoradiotherapy
Time frame: The primary analysis will be held 5-years after the last patient was enrolled.
If the remnant lesion in the esophagus or a recurrent lesion after complete response (CR) can be curatively removed by salvage EMR/ESD, it is not an event, and other progressions and deaths are events.
Time frame: The primary analysis will be held 5-years after the last patient was enrolled.
From date of randomization to date of death, approximately 5 years.
Time frame: The primary analysis will be held 5-years after the last patient was enrolled.
From date of randomization to date of progression or death, whichever occurs first, approximately 5 years.
Time frame: The primary analysis will be held 5-years after the last patient was enrolled.
CR was defined as disappeared primary tumors without the presence of ulceration or malignant cells in biopsy specimens under endoscopy.
Time frame: The primary analysis will be held 5-years after the last patient was enrolled.
From date of randomization to date of esophagectomy or death, whichever occurs first, approximately 5 years.
Time frame: The primary analysis will be held 5-years after the last patient was enrolled.
Number of participants with treatment-related adverse events during CRT as assessed by CTCAE v4.0
Time frame: The primary analysis will be held 5-years after the last patient was enrolled.
Number of participants with treatment-related adverse events after termination of CRT as assessed by CTCAE v4.0
Contact information is provided by the study sponsor or research team.
National Cancer Center, Japan
Other Gov
A Randomized Controlled Phase III Trial of Comparing Local Field With Additional Prophylactic Irradiation in Chemoradiotherapy for Clinical-T1bN0M0 Esophageal Cancer
Acronym: ARMADILLO
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05028725
Carcinoma, Carcinoma, Squamous Cell
Dar es Salaam, Mloganzila, Tanzania
View Trial DetailsNCT07090499
Adenocarcinoma, Adenocarcinoma Of Esophagus
Duarte, California, United States
View Trial DetailsNCT07554521
Advanced Gastroesophageal Adenocarcinoma, Advanced Unresectable Gastric Adenocarcinoma
Los Angeles, California, United States
View Trial DetailsNCT05208762
Adenocarcinoma, Breast Diseases
Birmingham, Alabama, United States
View Trial Details